SAN DIEGO -- Use of neoadjuvant axitinib (Inlyta) resulted in significant reductions in tumor size and complexity, enabling partial nephrectomy in a cohort of patients with highly complex renal masses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results